The aberrant activation of the p44/42 MAPK pathway, also known as RAS-RAF-MEK-ERK signaling, in KRAS-driven cancers, has generated significant interest in targeting the downstream effectors of this cascade as a therapeutic approach [11–13]. Here, KRAS is linked to cancer.